If you develop any irritation or feel unwell after the patch test,donot use the product
CEO Andrew Dudum reiterated a long term revenue target of roughly $6.5 billion by 2030, with substantial contributions expected from GLP-1 drugs and related metabolic care offerings
Overweight (body mass index equal to or greater than 27) with at least one weight-related problem such as high cholesterol, hypertension, or type 2 diabetes
Early identification allows for timely interventions including lifestyle and pharmacologic strategies that address metabolic dysfunction
We built this tracker to give patients an easier way to navigate GLP-1 shortages, by: 1 Clearly showing which GLP-1s are currently in shortage by drug and dose 2 Making it easy for everyone to crowdsource where and when they find GLP-1 supply or, when they cannot, to submit a shortage report to the FDA 3 Letting anyone join our Supply List that sends real-time alerts when GLP-1 supply is located at a pharmacy near them 4 Sending automated notifications to patients and providers who sign-up letting them know when a drugs status changes on the FDAs list
Last Updated: Nov 18, 2025
